Tusk Therapeutics awarded £2.5 million Grant from Innovate UK’s “Biomedical Catalyst Round 2 Late Stage”

Novel CD38 Targeting Cancer Immunotherapy Grant allows Tusk to accelerate its strongly differentiated anti-CD38 immunotherapy development program for treatment of solid cancers London and Stevenage, UK – 14 November 2017: Tusk Therapeutics is an immuno-oncology company with a focus on harnessing the power of the immune system to fight cancer through the development of novel immune modulating therapeutics.  Tusk today … Read More